#United States #New York #Securities Class Action #Regeneron Pharmaceuticals #SueWallSt

Regeneron Pharmaceuticals Class Action Lawsuit: A Call to Investors

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has recently become the focal point of a significant securities class action lawsuit, alerting investors to allegations surrounding the company’s Phase III Fianlimab-Libtayo clinical trial. This lawsuit highlights the complex relationship between corporate disclosures, investor confidence, and the subsequent financial repercussions when essential information is either delayed or miscommunicated.

The core of the lawsuit pertains to the events that transpired between August 1, 2025, and May 15, 2026. During this period, Regeneron is accused of providing misleading information regarding the status of its Phase III clinical trial—the Fianlimab-Libtayo study. Investors have reported experiencing considerable financial losses, as REGN shares plummeted from $731.77 per share on April 28, 2026, to $629.68 on May 18, 2026, marking a staggering decline of over $102 per share, or approximately 13.95%.

Allegations of Misleading Information

According to the lawsuit, Regeneron's public statements regarding trial progress appeared optimistic, framing slower event accruals as potentially indicative of favorable outcomes. However, as later revealed, the Phase III study required a larger patient population to generate statistically significant results. The shift in protocol and subsequent failure to meet the primary endpoint led to investor disenchantment and significant losses.

Key Dates and Events

• - August 1, 2025: Regeneron announced completion of enrollment for the PFS (Progression-Free Survival) cohort, but cited delays due to slowed blinded event accrual.
• - November 17, 2025: Company representatives underestimated the impact of this slower event rate, continuing to suggest strength in test arms, which misled investors about the trial's viability.
• - April 29, 2026: Regeneron disclosed changes to the PFS analysis, resulting in a steep drop of $45.41 in share value.
• - May 15, 2026: The announcement that the trial did not reach statistical significance saw REGN shares fall by a further $68.57 per share on May 18, leading to alarm among shareholders.

The timing and substance of these disclosures have been criticized for contributing to a misalignment between what investors believed about the trial's potential and the reality as it unfolded.

Importance of Timely Disclosure

The complaint underscores the critical nature of transparent and timely information regarding clinical trial developments, especially for a study that has substantial implications for investor confidence and financial stability. The legal woes Regeneron faces highlight a broader concern regarding accountability in clinical trial disclosures and the protection of shareholder interests.

Joseph E. Levi, Esq., representing potential plaintiffs, emphasized that the sequence of these disclosure events significantly affected how shareholders assessed trial risks. Each delayed or misleading update shifted investor perceptions, ultimately resulting in financial impairments as the reality of the trial's progression came to light.

Next Steps for Investors

Investors who acquired shares of REGN within the specified timeframe may be eligible to recover some of their losses through this class action. The deadline to seek lead plaintiff status in the class action lawsuit is September 14, 2026. Shareholders are encouraged to maintain their trade confirmations and brokerage statements as documentation of their investments during this period.

For those who may have sold their REGN shares prior to the lawsuit, eligibility for recovery depends on when the shares were purchased rather than their current holding status. Interested investors can contact Joseph E. Levi at SueWallSt for additional information about their rights and potential for recovery benefits.

This lawsuit underscores the imperative for corporations to uphold transparency in their communications to investors, especially in the high-stakes realm of biotechnology and pharmaceuticals. As the litigation unfolds, it serves as a reminder for both investors and companies about the need for clarity and accountability in financial disclosures, ensuring that markets remain fair and efficient.

For more information on this lawsuit and how to participate, investors can reach out to Levi & Korsinsky LLP at (888) SueWallSt or visit their website.